Optimer Pharmaceuticals



		Subscribe to RSS feed 2010 \| 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2002 \| 2001 \| (12.17.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference (11.25.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference (11.10.2008) SAN DIEGO, CA Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80 (11.5.2008) SAN DIEGO, CA Optimer Pharmaceuticals Reports Third Quarter 2008 Financial Results (10.29.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at Oppenheimer Annual Healthcare Conference (10.20.2008) SAN DIEGO, CA Data from Optimer Pharmaceuticals Prulifloxacin Phase 3 Trial in Travelers Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting (9.10.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at Two Upcoming Investor Conferences (9.2.2008) SAN DIEGO, CA Optimer Pharmaceuticals Completes Enrollment in Second Prulifloxacin Phase 3 Clinical Trial (8.28.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference (8.6.2008) SAN DIEGO, CA Optimer Pharmaceuticals Reports Second Quarter 2008 Financial Results (7.30.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at August 2008 Investor Conferences (7.28.2008) SAN DIEGO, CA Optimer Pharmaceuticals Completes $14.8 Million Registered Direct Offering (7.23.2008) SAN DIEGO, CA Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection (7.21.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Raise $12.2 Million in Registered Direct Offering (7.17.2008) SAN DIEGO, CA Optimer Pharmaceuticals Announces Change to Board of Directors (7.16.2008) SAN DIEGO, CA Optimer Pharmaceuticals Announces Positive Results in Prulifloxacin Phase 3 Study (6.26.2008) SAN DIEGO, CA Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress (6.17.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at Two Upcoming Investor Conferences (6.11.2008) SAN DIEGO, CA Optimer to Present Additional Data from OPT-80 Phase 2A Study for Clostridium difficile Infection at Anaerobe 2008 Congress (6.3.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at Needham Biotechnology & Medical Technology Conference (5.27.2008) SAN DIEGO, CA Optimer Pharmaceuticals Receives Polymorph Patent for Lead Product Candidate OPT-80 (5.7.2008) SAN DIEGO, CA Optimer Pharmaceuticals Reports First Quarter 2008 Financial Results (5.6.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Present at Upcoming Investor Conferences (4.21.2008) BARCELONA, SPAIN Clostridium difficile Infection 'Epidemic' Leads to Calls for Emerging Next-Generation Therapies (4.15.2008) SAN DIEGO, CA Optimer Pharmaceuticals Sponsors ECCMID Symposium on Clostridium difficile-Associated Disease: Current Treatment and Challenges (4.8.2008) SAN DIEGO, CA Optimer Pharmaceuticals Receives Notice of Allowance for OPT-80 Patent Application (4.2.2008) SAN DIEGO, CA Optimer Pharmaceuticals Announces Peer-Reviewed Publication of OPT-80 Phase 1 Clinical Results for the Treatment of Clostridium Difficile Infection (3.26.2008) SAN DIEGO, CA Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results (3.19.2008) SAN DIEGO, CA Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results (3.11.2008) SAN DIEGO, CA Optimer Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of Prulifloxacin in Patients with Travelers� Diarrhea (1.7.2008) SAN DIEGO, CA Optimer Pharmaceuticals Awarded Grant from the National Institutes of Health for Development of OPT-80 to Treat Deadly Hospital Associated Infection

(6.3.2008) SAN DIEGO, CA

Optimer Pharmaceuticals to Present at Needham Biotechnology & Medical Technology Conference

SAN DIEGO, CA � June 3, 2008 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) is scheduled to present at the Seventh Annual Needham Biotechnology & Medical Technology Conference at the New York Palace Hotel in New York City on June 11, 2008, 11:00 a.m. Eastern Time.

A live audio webcast of this presentation will be accessible on the Company�s website at www.optimerpharma.com, under the investors section. A replay of this presentation will be available at the same location for thirty days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer has two late-stage anti-infective product candidates. OPT‑80, currently in two pivotal Phase 3 clinical trials, is being developed for the treatment of Clostridium difficile infection, the most common hospital-acquired diarrhea. Prulifloxacin, also in two pivotal Phase 3 clinical trials, is an antibiotic being developed for the treatment of travelers� diarrhea, a form of infectious diarrhea. Additional information regarding Optimer can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

Porter Novelli Life Sciences

Jason I. Spark, Account Director

619-849-6005